Skip to main content
CREO MEDICAL GROUP PLC logo

CREO MEDICAL GROUP PLC — Investor Relations & Filings

Ticker · CREO ISIN · GB00BZ1BLL44 LEI · 213800H188ZDCWWXFA21 IL Manufacturing
Open in API
Filings indexed 300 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country GB United Kingdom
Listing IL CREO

About CREO MEDICAL GROUP PLC

https://www.creomedical.com/

Creo Medical Group PLC is a medical device company specializing in the development and commercialization of minimally invasive electrosurgical devices for therapeutic endoscopy. The company's core technology platform integrates advanced bipolar radiofrequency for precise tissue cutting with high-frequency microwave energy for controlled coagulation. Its principal products, such as the Speedboat device, are designed to enable clinicians to perform complex procedures like endoscopic submucosal dissection (SSD) to remove gastrointestinal lesions. By providing alternatives to traditional surgery, Creo Medical aims to improve patient outcomes, reduce recovery times, and lower healthcare costs. The company also provides extensive clinical education and training programs to support healthcare professionals in adopting its advanced energy technologies.

Recent filings

Filing Released Lang Actions
KOL presentations on Creo Core Products at DDW
Regulatory Filings
2026-04-30 English
UK private hospital use Speedboat for cancer case
Regulatory Filings Classification · 1% confidence The document is a press release distributed via the London Stock Exchange’s Regulatory News Service (RNS). It announces a product adoption milestone (first UK private hospital use of the Speedboat procedure) rather than presenting financial results, governance changes, voting outcomes, or any formal report. It is therefore a general regulatory announcement that does not fit the more specific categories and falls under the fallback RNS category.
2026-04-29 English
Positive Q1 trading update
Earnings Release Classification · 1% confidence The document is an RNS announcement titled "Positive Q1 trading update" providing headline revenue growth and operational highlights for the quarter ended 31 March 2026. It contains key financial metrics (60% year-on-year revenue growth, plan for full-year growth) but does not present a full interim report with detailed financial statements. This corresponds to an initial earnings/trading release rather than a comprehensive interim report. Therefore, it is classified as an Earnings Release (ER). Q1 2026
2026-04-22 English
Appointment of Joint Corporate Broker
Regulatory Filings Classification · 1% confidence The document is an official announcement from Creo Medical Group plc regarding the appointment of a new Joint Corporate Broker. This type of corporate update, which involves changes to professional advisors or service providers, does not fit into specific categories like M&A, Board changes, or Share issues. Therefore, it is classified as a general regulatory announcement under the RNS category.
2026-02-24 English
FY25 Trading Update
Earnings Release Classification · 1% confidence The document is a 'FY25 Trading Update' issued by Creo Medical Group PLC. It provides preliminary financial highlights (revenue growth, operating costs, operating loss) and operational updates for the fiscal year ended 31 December 2025. It explicitly states it is a 'Trading Update' and mentions that full year results will be announced later in April 2026. According to the filing definitions, an initial announcement of periodical financial results (key highlights only) is classified as an Earnings Release (ER). FY 2025
2026-01-20 English
Award of Shares under Share Incentive Plan
Director's Dealing Classification · 1% confidence The document is an RNS (Regulatory News Service) announcement from Creo Medical Group PLC regarding the acquisition of shares by executive directors (CEO and CFO) under a Share Incentive Plan (SIP). It explicitly includes the 'Details of PDMR' (Persons Discharging Managerial Responsibilities) and transaction tables required by the Market Abuse Regulation for director dealings. While it mentions the SIP, the core purpose is to report the personal share transactions of company directors, which falls under the 'Director's Dealing' category.
2026-01-14 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.